{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:17:00Z","timestamp":1787318220849,"version":"build-2736575974"},"publisher-location":"Berlin, Heidelberg","reference-count":7,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642280955","type":"print"},{"value":"9783642280962","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/8904_2011_106","type":"book-chapter","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T08:30:24Z","timestamp":1323505824000},"page":"109-112","source":"Crossref","is-referenced-by-count":12,"title":["Severe Infusion Reactions to Fabry Enzyme Replacement Therapy: Rechallenge After Tracheostomy"],"prefix":"10.1007","author":[{"given":"K.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bleasel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,11]]},"reference":[{"key":"106_CR1","unstructured":"Barbey F, Livio F (2006) Safety of enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford, Chapter 41. \n                  http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11617\/"},{"key":"106_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001a) Safety and efficacy of recombinant human \u03b1-galactosidase A \u2013 replacement therapy in Fabry's disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"106_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE et al (2001b) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711\u2013722","journal-title":"Am J Hum Genet"},{"key":"106_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollack CEM, Donker-Koopman WE, Strijland A, Aerts JMFG (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int 66:1589\u20131595","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"106_CR5","first-page":"330","volume":"28","author":"U Ramaswami","year":"2005","unstructured":"Ramaswami U, Wendt S, Parini R et al (2005) Safety of enzyme replacement therapy with agalsidase alfa in children with Fabry disease. J Inherit Metab Dis 28(Suppl 1):330","journal-title":"J Inherit Metab Dis"},{"key":"106_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd818","volume":"1","author":"H Schellekens","year":"2002","unstructured":"Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457\u2013462","journal-title":"Nat Rev Drug Discov"},{"key":"106_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al (2004) International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"}],"container-title":["JIMD Reports","JIMD Reports - Case and Research Reports, 2012\/2"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/8904_2011_106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T10:58:00Z","timestamp":1557485880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/8904_2011_106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783642280955","9783642280962"],"references-count":7,"URL":"https:\/\/doi.org\/10.1007\/8904_2011_106","relation":{},"ISSN":["2192-8304","2192-8312"],"issn-type":[{"value":"2192-8304","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}